DGAP-News

EVOTEC AG: 'LAB282' AWARDED FIRST PROJECTS

DGAP-News: Evotec AG / Key word(s): Miscellaneous EVOTEC AG: 'LAB282' AWARDED FIRST PROJECTS 21.02.2017 / 07:29 The issuer is solely responsible for the content of this announcement. - Oxford University and Evotec's drug discovery partnership launched last November to accelerate drugs to market begins making awards

Hamburg, Germany, 21 February 2017:

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) is
pleased to announce that LAB282, the £ 13 m (over EUR 15 m) drug discovery
partnership with Oxford University, has made its first wave of awards,
backing projects targeting cardiovascular diseases and infectious diseases.

Launched last year in November as a partnership between Oxford University,
Evotec, Oxford University Innovation Ltd and Oxford Sciences Innovation
plc, LAB282 aids the rapid translation of research outputs into new drug
discovery and development programmes. It draws on expertise provided by
Evotec and combines it with pre-clinical proof-of-concept grant funding to
accelerate projects into a position where they can be commercialised and
scaled up efficiently and effectively.

Out of a pool of high-quality project proposals across various therapeutic
areas and encompassing different therapeutic modalities, two projects were
chosen. The two grant winners will be conducting further research into:

- "Drugs from bugs" - A project developing evasins, a potential treatment
for cardiovascular and autoimmune diseases derived from the saliva of
ticks;

- DarTG - A potential new target for the development of antibiotics that
could shut down tuberculosis and several other pathogens.

Evotec will exclusively contribute its drug discovery expertise and
platforms to the selected projects and together with Oxford University and
its academic researchers develop them further with the aim to have a
pre-clinical proof of concept for new drugs.

The next round of grants awards is due in June 2017.